Literature DB >> 18021007

Poly(adp-ribose) polymerase-1 regulates Tracp gene promoter activity during RANKL-induced osteoclastogenesis.

Guillaume E Beranger1, David Momier, Nathalie Rochet, Georges F Carle, Jean-Claude Scimeca.   

Abstract

UNLABELLED: The Tracp gene encodes an acid phosphatase strongly upregulated during osteoclastogenesis on RANKL treatment. Using the mouse osteoclastic model RAW264.7, we studied Tracp gene expression, and we identified PARP-1 as a transcriptional repressor negatively regulated by RANKL during osteoclastogenesis.
INTRODUCTION: The Tracp gene encodes an acid phosphatase strongly expressed in differentiated osteoclasts. TRACP enzyme has a dual role and is involved in (1) the regulation of the biological activity of the bone matrix phosphoproteins osteopontin and bone sialoprotein and (2) the intracellular collagen degradation. Based on our previous work on Tcirg1 gene expression, and using data available in the literature, we focused on a 200-bp sequence located upstream the Tracp gene transcriptional start to identify binding activities.
MATERIALS AND METHODS: We first performed siRNA transfections and RAW264.7 cell treatment with an inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) activity. After EMSA and supershift experiments, we measured the promoter activity of wildtype and mutant constructs throughout the osteoclastic differentiation.
RESULTS: We first showed that depleting PARP-1 mRNA in the pre-osteoclastic cell line RAW264.7 results in an increase of both matrix metalloproteinase 9 and TRACP mRNA expression (3.5- and 2.5-fold, respectively). Moreover, in response to 3-aminobenzamide treatment, we measured a weak stimulation of MMP9 mRNA expression, whereas up to a 2-fold enhancement above the control condition of TRACP mRNA expression was observed. We next identified in the -839/-639 Tracp promoter region a PARP-1 binding site, and supershift experiments showed the interaction of a PARP-1 binding activity with the Tracp promoter sequence -830/-808. Finally, RAW264.7 cell transfection with a promoter construct mutated for this PARP-1 interacting sequence showed the functionality of this site within intact pre-osteoclastic cells.
CONCLUSIONS: In this study, we provide evidence that the transcriptional activity of the Tracp gene, in pre-osteoclastic cells, is negatively regulated by the binding of PARP-1 protein to a potential consensus sequence located in its promoter region. Taken together with our previous results related to the control of Tcirg1 gene expression, our data suggest that PARP-1 exerts a pivotal role in the basal repression of genes that are upregulated during RANKL-induced osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18021007     DOI: 10.1359/jbmr.071111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  Specific expression of BMP2/4 ortholog in biomineralizing tissues of corals and action on mouse BMP receptor.

Authors:  Didier Zoccola; Aurélie Moya; Guillaume E Béranger; Eric Tambutté; Denis Allemand; Georges F Carle; Sylvie Tambutté
Journal:  Mar Biotechnol (NY)       Date:  2008-09-16       Impact factor: 3.619

2.  Identification of miR-708-5p in peripheral blood monocytes: Potential marker for postmenopausal osteoporosis in Mexican-Mestizo population.

Authors:  Aldo H De-La-Cruz-Montoya; Eric G Ramírez-Salazar; Mayeli M Martínez-Aguilar; Pablo M González-de-la-Rosa; Manuel Quiterio; Cei Abreu-Goodger; Jorge Salmerón; Rafael Velázquez-Cruz
Journal:  Exp Biol Med (Maywood)       Date:  2018-10-15

3.  RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.

Authors:  Jianfeng Chen; Yong Sun; Xia Mao; Qizhan Liu; Hui Wu; Yabing Chen
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

4.  NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.

Authors:  Chao Qu; Sheri L Bonar; Cynthia L Hickman-Brecks; Samer Abu-Amer; Matthew D McGeough; Carla A Peña; Lori Broderick; Chang Yang; Susan K Grimston; Jacqueline Kading; Yousef Abu-Amer; Deborah V Novack; Hal M Hoffman; Roberto Civitelli; Gabriel Mbalaviele
Journal:  FASEB J       Date:  2014-12-04       Impact factor: 5.191

Review 5.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

6.  Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast maturation.

Authors:  C Wang; C Qu; Y Alippe; S L Bonar; R Civitelli; Y Abu-Amer; M O Hottiger; G Mbalaviele
Journal:  Cell Death Dis       Date:  2016-03-24       Impact factor: 8.469

Review 7.  Role of APD-Ribosylation in Bone Health and Disease.

Authors:  Chun Wang; Gabriel Mbalaviele
Journal:  Cells       Date:  2019-10-05       Impact factor: 6.600

8.  PARP1 Hinders Histone H2B Occupancy at the NFATc1 Promoter to Restrain Osteoclast Differentiation.

Authors:  Chun Wang; Jianqiu Xiao; Kathrin Nowak; Kapila Gunasekera; Yael Alippe; Sheree Speckman; Tong Yang; Dustin Kress; Yousef Abu-Amer; Michael O Hottiger; Gabriel Mbalaviele
Journal:  J Bone Miner Res       Date:  2020-01-07       Impact factor: 6.741

9.  PARP-1 and YY1 are important novel regulators of CXCL12 gene transcription in rat pancreatic beta cells.

Authors:  Jelena Marković; Nevena Grdović; Svetlana Dinić; Teodora Karan-Djurašević; Aleksandra Uskoković; Jelena Arambašić; Mirjana Mihailović; Sonja Pavlović; Goran Poznanović; Melita Vidaković
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

10.  ARTD1 regulates osteoclastogenesis and bone homeostasis by dampening NF-κB-dependent transcription of IL-1β.

Authors:  Agnieszka Robaszkiewicz; Chao Qu; Ewelina Wisnik; Tomasz Ploszaj; Ali Mirsaidi; Friedrich A Kunze; Peter J Richards; Paolo Cinelli; Gabriel Mbalaviele; Michael O Hottiger
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.